Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a Canadian cohort study showed.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Factors associated with multi-b/tsDMARD failure among patients with PsA included female sex, obesity, depression, axial disease, and increased disease activity.

1 The prospective, multicenter study is published in the Journal of Psoriasis and Psoriatic Arthritis. “Female sex was associated with shorter overall drug survival for all biologics combined ...

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

highlighting the antibody-based drug’s efficacy as a first-line option for patients with active psoriatic arthritis ((PsA)). JNJ said that Tremfya, which is already approved in the U.S. for PsA ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, ...

The study also showed that rats exposed to alcohol had higher levels of PDE4 genes in their brains, strengthening the ...